Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
|
30897165 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results illustrate that the RFNs can target to disrupt bcr-abl gene and may provide a new therapeutic option for CML patients affiliated by drug resistance or disease relapse.
|
31138265 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
|
30675008 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1 signal patterns were analyzed using FISH in 243 CML-chronic phase (CML-CP), 17 CML-blast phase (CML-BP) and 52 BCR-ABL1 positive acute lymphoblastic leukemia (ALL) patients.
|
31594548 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia.
|
31293972 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chronic myeloid leukemia (CML) has long been thought to be the model disease for immunotherapy with its characteristic BCR-ABL fusion protein.
|
30855193 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
We explore the potential pathways and events that may cooperate with BCR-ABL1 to answer these questions but also challenge the fundamental tenet that BCR-ABL1 is always the sole event initiating CML.
|
31696382 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Deletion of the Klf4 gene severely abrogated the maintenance of BCR-ABL1(p210)-induced CML by impairing survival and self-renewal in BCR-ABL1+ CD150+ lineage-negative Sca-1+ c-Kit+ leukemic cells.
|
31515251 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This study highlights the need for BCR-ABL gene sequence analysis to detect the mutations in CML patients in order to properly guide the therapy.
|
30787317 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
All studies of treatment-free remission (TFR) in patients with chronic myeloid leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have focussed on patients with stable MR4 (BCR-ABL to ABL ratio ≤0·01%).
|
31201085 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
|
31801582 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
CML is associated with the fusion of BCR (on chromosome 22) and ABL1 (on chromosome 9) resulting in the BCR-ABL1 fusion gene.
|
31447069 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BCR-ABL1 tyrosine kinase inhibitors (TKIs) are selective therapies for patients with chronic myeloid leukemia (CML) and induce deep molecular response (DMR).
|
31530245 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time PCR methods are commonly used to monitor BCR-ABL transcript levels in patients with chronic myelogenous leukemia.
|
30347270 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-positive leukemias have historically been classified as either chronic myelogenous leukemia or Ph+ acute lymphoblastic leukemia.
|
31136068 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
We present these findings in relation to the discovery and therapeutic targeting of BCR-ABL1 in chronic myeloid leukemia.
|
31551508 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
A microfluidic mixing technology was used to obtain reproducible ionizable cationic LNPs loaded with siRNA molecules targeting the BCR-ABL fusion oncogene found in CML.
|
31104089 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Most patients with CML harbor either the e13a2 or the e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts.
|
30630459 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The constitutive BCR-ABL1 active protein fusion has been identified as the main cause of chronic myeloid leukemia.
|
30877503 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia.
|
30267776 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Defining the presence of BCR-ABL transcript in suspected myeloproliferative neoplasm is essential in establishing chronic myeloid leukemia.
|
30772299 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The BCR-ABL1 oncogene is associated with chronic myeloid leukemia (CML) pathogenesis, but the molecular mechanisms that initiate leukemogenesis are still unclear.
|
30738963 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Point mutations in the ABL1 kinase domain (KD) are an important mechanism of TKI resistance in CML.
|
31463864 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
TOPK inhibitor OTS514 suppressed proliferation of BCR/ABL‑positive cell lines and colony formation of CD34‑positive cells from patients with CML compared with lymphoma patients without bone marrow involvement.
|
30864683 |
2019 |
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, the detailed mechanisms through which SETD2 confers chronic myeloid leukaemia progression and resistance to therapy targeting on BCR-ABL remain unclear.
|
31054182 |
2019 |